Search clinical trials for: Sitagliptin (Januvia)

Total 861 results

Justine Boles
European and Developing Countries Clinical Trials Partnership (EDCTP)

Completed

Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST)

HIV | Human Immunodeficiency Virus

Kenya, Malawi, Uganda, Zambia, Zimbabwe
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin Add-on to Insulin Background Therapy

Diabetes Mellitus, Type 2

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
LG Life Sciences

Completed

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (GUARD)

Type 2 DM Patients With Moderate or Severe Renal Impairment

Korea, Republic of
Beijing Chao Yang Hospital

Unknown

Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

Obesity | Type 2 Diabetes
Ministry of Public Health, Argentina
Aix Marseille Université; Instituto de Biología y Medicina Experimental, IBYME...

Unknown

Effect of Linagliptin on TRL Metabolism

Type 2 Diabetes

Argentina
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy
Long Min,MD

Unknown

Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers (DPP4i)

Diabetic Foot Ulcer

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Diabetes Mellitus, Type 2

Germany, Spain, United States, Canada, Taiwan, Korea, Republic of, Finland, Denmark, France, Japan, Philippines, Vietnam
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Healthy

Germany
Southern California College of Optometry at Marshall...

Recruiting

Eyelid Androgen Treatment in Dry Eye

Aqueous Tear Deficiency | Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)

United States
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
University of Copenhagen
Hvidovre University Hospital

Completed

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes (NEPT2D)

Type2 Diabetes

Denmark
University of Pavia
IRCCS Policlinico S. Matteo

Unknown

Triple Therapy in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Italy
Dong Wha Pharmaceutical Co. Ltd.

Completed

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers

Healthy Subjects

Korea, Republic of
National University of Malaysia

Completed

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

PreDiabetes | Type 2 Diabetes

Malaysia
Prof. Dr. Thomas Forst

Completed

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Type2 Diabetes Mellitus

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, India, Israel, Malaysia, Mexico, Philippines, Puerto Rico, Russian Federation, Sri Lanka, Thailand, Ukraine
Dong Wha Pharmaceutical Co. Ltd.

Completed

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

Healthy Subjects

Korea, Republic of
AstraZeneca

Completed

Bioequivalence Study

Diabetes

United States
ikfe-CRO GmbH
AstraZeneca; IKFE Institute for Clinical Research and Development

Unknown

Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Germany
Johnson & Johnson Consumer and Personal Products...

Completed

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

Androgenetic Alopecia

United States
Nicolai Jacob Wewer Albrechtsen

Completed

The Effects of Neprilysin on Glucagon-like Peptide-1 (NEP)

Heart Failure | Diabetes

Denmark
Merck Sharp & Dohme LLC

Completed

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Diabetes Mellitus, Non-Insulin-Dependent
University of Campinas, Brazil

Completed

Short-term Effect of Extended-release Niacin on Endothelial Function.

Hypoalphalipoproteinemia

Brazil
Ohio State University Comprehensive Cancer Center

Completed

2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer

Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IV A Bladder Cancer | Stage IV A Rectal Cancer | Stage IV B Colon Cancer | Stage IV B Rectal Cancer

United States
Nick Giannoukakis, PhD
University of South Florida; AstraZeneca; University of Pittsburgh; National Institutes...

Completed

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Type 2 Diabetes Mellitus | Insulin Resistance

United States
Emory University
American Diabetes Association

Completed

ADA Linagliptin in Long Term Care

Diabetes

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Healthy

Germany
International Bio service

Not yet recruiting

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Healthy Volunteer
AstraZeneca

Completed

Korean Post-marketing Surveillance for Onglyza®

Diabetes Mellitus, Type 2

Korea, Republic of
AstraZeneca

Completed

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Diabetes Mellitus, Type 2

Austria, Greece, Hungary, Japan, Portugal, Romania, Spain
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

A Study To Evaluate Methods To Evaluate Back Pain

Pain

United States
AstraZeneca

Completed

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States, Chile, Argentina, Brazil, Canada, Mexico, Puerto Rico, Taiwan, Australia
Boehringer Ingelheim

Completed

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Boehringer Ingelheim

Completed

Empa/Lina FDC Food Effect Study (Japan)

Healthy

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes Mellitus, Type 2

United States, Mexico, Canada, United Kingdom, India, Belgium, Taiwan
Zhujiang Hospital

Recruiting

Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD (HHTN)

Nonalcoholic Fatty Liver Disease | Type2 Diabetes Mellitus

China
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine (RESCATHEME)

Insulin Resistance | Prediabetic State | Impaired Glucose Tolerance

Mexico
Northwell Health

Withdrawn

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes | SGLT-2 Inhibitors | Advanced Glycation End Products
AstraZeneca

Completed

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Puerto Rico, Taiwan, Australia
Shandong Provincial Hospital
Chinese Medical Association

Unknown

Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity

Prediabetes

China
IlDong Pharmaceutical Co Ltd

Recruiting

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Type 2 Diabetes

Germany

Search clinical trials for: Sitagliptin (Januvia)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations